Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 368,554 |
|
|||||
| News | (11) | ||||||
| Day High | 150.78 | Low High |
|||||
| Day Low | 147.78 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc | ALNY | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.36 | -0.91% | 148.0415 | 15:41:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 149.30 | 147.78 | 150.78 | 150.24 | 149.40 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,917 | 368,554 | US$ 149.16 | US$ 54,971,727 | - | 141.975 - 218.88 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:41:06 | formt | 100 | US$ 148.0415 | USD |
Alnylam Pharmaceuticals (ALNY) Options Flow Summary
Alnylam Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.92B | 125.95M | - | 1.83B | -440.24M | -3.50 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alnylam Pharmaceuticals News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALNY Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 151.28 | 152.67 | 144.73 | 149.39 | 615,814 | -3.24 | -2.14% |
| 1 Month | 145.21 | 155.49 | 141.975 | 148.61 | 494,822 | 2.83 | 1.95% |
| 3 Months | 156.49 | 161.3092 | 141.975 | 150.07 | 592,374 | -8.45 | -5.40% |
| 6 Months | 163.82 | 199.38 | 141.975 | 162.51 | 701,228 | -15.78 | -9.63% |
| 1 Year | 191.38 | 218.88 | 141.975 | 171.96 | 645,912 | -43.34 | -22.65% |
| 3 Years | 135.25 | 242.97 | 117.58 | 180.36 | 754,583 | 12.79 | 9.46% |
| 5 Years | 67.25 | 242.97 | 65.81 | 157.75 | 714,262 | 80.79 | 120.14% |
Alnylam Pharmaceuticals Description
| Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
